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Abstract 
Background:  The factors determining differential HIV disease outcome among individuals expressing protective  
HLA alleles such as HLA-B*27:05 and HLA-B*57:01 remain unknown. We here analyse two HIV-infected subjects 
expressing both HLA-B*27:05 and HLA-B*57:01. One subject maintained low-to-undetectable viral loads for more 
than a decade of follow up. The other progressed to AIDS in < 3 years.
Results:  The rapid progressor was the recipient within a known transmission pair, enabling virus sequences to be 
tracked from transmission. Progression was associated with a 12% Gag sequence change and 26% Nef sequence 
change at the amino acid level within 2 years. Although next generation sequencing from early timepoints indi-
cated that multiple CD8+ cytotoxic T lymphocyte (CTL) escape mutants were being selected prior to superinfec-
tion, < 4% of the amino acid changes arising from superinfection could be ascribed to CTL escape. Analysis of an 
HLA-B*27:05/B*57:01 non-progressor, in contrast, demonstrated minimal virus sequence diversification (1.1% Gag 
amino acid sequence change over 10 years), and dominant HIV-specific CTL responses previously shown to be effec-
tive in control of viraemia were maintained. Clonal sequencing demonstrated that escape variants were generated 
within the non-progressor, but in many cases were not selected. In the rapid progressor, progression occurred despite 
substantial reductions in viral replicative capacity (VRC), and non-progression in the elite controller despite relatively 
high VRC.
Conclusions: These data are consistent with previous studies demonstrating rapid progression in association 
with superinfection and that rapid disease progression can occur despite the relatively the low VRC that is typically 
observed in the setting of multiple CTL escape mutants.
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Background
Outcome in HIV infection is strongly influenced by the 
particular HLA alleles that are expressed, the most pro-
tective of which are HLA-B*27:05 and HLA-B*57:01 [1, 
2]. The mechanism by which these HLA alleles confer 
protection is related to the presentation of a broad array 
of epitopes that enable CD8+ cytotoxic T lymphocytes 
(CTL) to recognise and kill HIV-infected target cells [2, 
3]. As HIV-specific CTL are likely to play a critical role 
in strategies designed to eradicate viral reservoirs [4], it 
remains important to define what features affect the abil-
ity of CTL to be effective in killing virus-infected cells. 
We here contrast HIV disease outcomes in two HIV-
infected subjects expressing both HLA-B*27:05 and 
HLA-B*57:01. One subject is a typical HIV non-progres-
sor, maintaining viral loads below the level of detection 
for more than a decade of follow up. The other subject 
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initially presented the characteristic phenotype of an 
HLA-B*27:05/57:01-positive HIV-infected subject, with a 
low viral load (65 copies/ml) and high absolute CD4+ T 
cell count (950 cells/mm3), but within 2.7 years had pro-
gressed rapidly to AIDS (CD4+ T cell count < 200 cells/
mm3).
Methods
Study subjects
The adult Caucasian transmission pair R096 (HLA-
A*02:01/A*11:01 B*13:02/B*51:01 C*03:03 C*06:02) 
and R097 (HLA-A*11:01/A*24:01 B*27:05/B*57:01 
C*02:02 C*06:02) and non-progressor RI088 (HLA-
A*01:01/A*03:01 B*27:05/B*57:01 C*02:02 C*06:02) were 
recruited from the Thames Valley Cohort, UK, previously 
described [5].
DNA and RNA extraction
Proviral and genomic DNA were extracted for proviral 
sequencing and HLA-typing respectively, using Pure-
Gene reagents according to the manufacturers instruc-
tions. Viral plasma RNA was extracted using the Qiamp 
Viral RNA Mini Kit (Qiagen, UK) according to the manu-
facturers instructions. For RNA extraction for ultra-deep 
sequencing, minor modifications to the manufacturers 
protocol were made, as previously described [6].
HLA‑typing
Four digit HLA Class I typing was performed at the 
CLIA/ASHI accredited laboratory of William Hilde-
brand, PhD, D (ABHI), University of Oklahoma Health 
Sciences Center. Locus specific PCR amplification of 
exons 2 and 3 and heterozygous sequencing were per-
formed from genomic DNA. Ambiguities were resolved 
by homozygous sequencing [7].
IFN‑γ ELISpot assays
Peripheral blood mononuclear cells were tested for 
responses to 410 18mer overlapping peptides spanning 
the B clade HIV proteome as previously described [8] 
using pools of 11–12 peptides followed by confirmatory 
assays using individual 18mer peptides.
Sanger sequencing of proviral DNA
The gag gene was amplified from proviral DNA 
using a nested touchdown PCR with BioTaq DNA 
polymerase (Bioline, UK) using the following prim-
ers: 5′-CTCTAGCAGTGGCGCCCGAA-3′ and 
5′-TCCTTTCCACATTTCCAACAGCC-3′ for the first 
round PCR and 5′-ACTCGGCTTGCTGAAGTGC-3′ 
and 5′ CAATTTCTGGCTATGTGCCC-3′ for the sec-
ond round PCR. Twenty cycles of denaturation at 94  °C 
for 15  s, annealing at 60  °C for 30  s and elongation at 
72 °C for 1 min were performed followed by another 20 
cycles with an annealing temperature of 57  °C. Purified 
PCR product was used to prepare sequencing templates 
using BigDye Terminator v3.1 reaction mix (Applied 
Biosystems, UK) and sequenced on an ABI 3730xl DNA 
Analyzer (Applied Biosystems, UK) by the Department 
of Zoology Sequencing Facility, University of Oxford. 
For clonal sequencing, purified PCR product was cloned 
into TOPO vectors using Zero Blunt TOPO PCR Clon-
ing Kit (Invitrogen, UK) and used to transform chemi-
cally competent One Shot TOP10 E. coli cells (Invitrogen, 
UK) according to the manufacturers instructions. Where 
possible, clones were selected from two independent 
PCRs to avoid PCR amplification bias. Selected colonies 
were cultured overnight in LB broth before proceeding 
with mini-prep plasmid DNA extraction using Montage 
96-well plasmid preparation kits (Millipore, US) accord-
ing to the manufacturers instructions. Plasmid DNA was 
used for sequencing template preparation as described 
above.
Ultra‑deep sequencing de novo assembly of consensus 
sequences and minor variant haplotype analysis
The full-length HIV genome was amplified in four frag-
ments from plasma RNA using Superscript III One-Step 
RT PCR Kit with Platinum Taq High Fidelity enzyme 
(Invitrogen, UK) as previously described [9]. Sequenc-
ing of pooled amplicons was performed using Illumina 
MiSeq 250 bp paired-end technology. Quality control of 
reads was performed using QUASR (http://sourceforge.
net/projects/quasr/) as previously described [6, 10, 11]. A 
de novo assembly was constructed using SPAdes version 
2.4.0 [12] and a consensus sequence was generated using 
Abacas version 1.3.1 and MUMmer version 3.2 [13]. 
Haplotypes in the epitope regions were determined using 
Vprofiler [12] by selecting reads that span the epitope 
region and which contain only accepted variants.
Phylogenetic analysis and recombination detection
Maximum likelihood phylogenetic trees were con-
structed using Mega 6.06 software under the General 
Time Reversible model of nucleotide substitution as 
determined by jModelTest version 0.1.1 [14] with 1000 
bootstrap replicates and viewed using FigTree v1.4.0 soft-
ware. Recombination analysis was performed using RDP 
4.46 (Recombination Detection Programme) [15] and 
SimPlot 3.5.1 [16].
Generation of recombinant gag‑protease HIV virions 
and viral replicative capacity assays (VRC)
Recombinant viral vectors expressing autologous-gag-
protease sequences from HLA-B*27:05/HLA-B*57:01+ 
individuals were constructed by transfecting gag-protease 
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amplicons into the Gag-Pro deleted HIV backbone 
ΔGag-Pro NL4-3 as previously described [17, 18]. Gag-
protease was amplified by nested PCR from plasma 
RNA using previously published primers [18]. The first 
round amplification was performed using Superscript III 
One-Step RT PCR Kit with Platinum Taq High Fidelity 
enzyme (Invitrogen, UK) followed by second round PCR 
using High Fidelity Platinum (Invitrogen, UK) accord-
ing to the manufacturers’ instructions. PCR product was 
purified using QIAquick PCR Purification Kit (Qiagen, 
UK) and sequenced by Sanger sequencing to confirm 
accurate amplification of the patient-derived gag-pro-
tease sequence.
The ΔGag-Pro NL4-3 was produced by introduc-
ing BstEII restriction enzyme sites on either side of the 
gag-protease-gene in NL4-3, followed by BstEII digest 
to delete gag-protease and allow self ligation of the plas-
mid [18]. For transfection, the plasmid was linearised 
by BstEII digest at 60  °C for 2  h. For each transfection, 
2.5  μg of purified gag-protease amplicon and 10  μg of 
linearised ΔGag-Pro NL4-3 were co-transfected into 2 
million CEM-GXR reporter cells [17, 19] by electropo-
ration (300  V, 500  μF capacitance and infinite resist-
ance). Recombinant viral cultures were expanded over 
1 month and viral spread measure by GFP expression 
detected by flow cytometry. Viral supernatant was col-
lected when > 30% of live cells were infected. Viral RNA 
extraction and gag-protease sequencing confirmed the 
correct sequence amplification of viral stocks. Viral titres 
were determined by infection of 1 million CEM-GXR 
cells with a standardized volume of viral supernatant and 
examining GFP expression after 48 h.
 Viral replicative capacity assays (VRC): CEM-GXR 
cells were infected in triplicate at a low multiplicity of 
infection (0.025% GFP+ cells at day 2). GFP expression 
was monitored daily by flow cytometry over 12 days.
Logistic curve modelling of viral replicative capacity data
Viral growth curves were modeled on the logistic curve 
function:
where θ1 represents the asymptotic y point, θ2 the mid-
point, and θ3 the scaling factor (rate of change) of the 
curve. Curves were fitted using the nonlinear regression 
nls function in R version 3.2.1, plotting the best fit logistic 
growth curve. To assess whether each parameter was sta-
tistically different when comparing curves, models were 
built where one of the parameters was fixed while the 
others were allowed to vary. A model where all param-
eters were allowed to vary was then fitted and a statistical 
y = m(x, θ)+ ε
= θ1/1+ exp (−θ2 + θ3x)
comparisons of parameters was made using ANOVA. 
The parameters used for the curves in Fig. 4 are shown in 
Additional file 1: Table 1, together with the statistics for 
the overall fit and for the separate parameters.
Sequence accession numbers
Sequence data has been deposited in Genbank under the 
accession numbers MF039091-MF039203.
Results
Rapid progression to AIDS in a transmission recipient 
expressing HLA‑B*27:05/B*57:01
The starting point for this study was the MSM trans-
mission pair R096/R097 (Fig.  1a, b). The transmission 
recipient, R097, expressed both HLA-B*27:05 and HLA-
B*57:01, both of which are strongly associated with slow 
progression to AIDS. The viral load in R097 at diagno-
sis (time 0) was 65 HIV RNA copies/ml plasma and the 
absolute CD4+ T cell count was 950 cells/mm3, reflect-
ing successful immune control of HIV. Over the next 
2–3  years, however, despite the co-expression of HLA-
B*27:05 and HLA-B*57:01, progression to AIDS (absolute 
CD4+ T cell < 200 cells/mm3) occurred rapidly, in asso-
ciation with viral loads increasing to > 105 copies/ml. The 
donor R096 at time 0 had a viral load of 221,839 copies/
ml and an absolute CD4+ T cell count of 260 cells/mm3 
and initiated antiretroviral therapy (ART) at this time.
To investigate why disease had progressed so rapidly in 
R097, and to seek evidence to support the clinical history 
suggesting transmission from R096 to R097, we ultra-
deep sequenced the virus in both individuals (Fig.  1c). 
Tight phylogenetic clustering of the viral sequences at 
‘time 0’ in R096 and R097 strongly supported the notion 
that R096/R097 were a transmission pair. Viral sequences 
from R097 post-progression (2.0–3.4  years after ‘time 
0’) clustered separately from the time 0 sequences. Gag 
sequences in R097 differed by 12% at the amino acid level 
in the 2 years from ‘time 0’ and Nef sequences by 26% at 
the amino acid level over this short time. These changes 
occurred in the context of a 12.5% nucleotide change 
across the full-length genome.
The direction of transmission from R096 to R097 was 
supported by the presence of virus encoding escape 
mutants in five HLA-B*51:01-restricted CTL epitopes in 
both subjects (Table 1). Since HLA-B*51:01 is expressed 
by R096 and not R097, this is consistent with the vari-
ant being selected initially in R096 and being transmit-
ted to R097. In four of the HLA-B*51:01-restricted 
epitopes, the variant we observed was the one most 
commonly seen in association with HLA-B*51:01, a so-
called HLA footprint [for example, I135T within the 
epitope TAFTIPSI (RT 128-135)] [20–22]. In contrast, 
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no HLA-B*57:01 or HLA-B*27:05-associated mutants 
were observed in the ‘time 0’ sequences in R096 and 
R097 (Table  2). One variant L268I was shared by R096 
and R097 at ‘time 0’, which lies within the HLA-B*27:05-
restricted epitope KRWIILGLNK (Gag 263-272). How-
ever, this mutant is an HLA-B*08:01-associated variant 
flanking the overlapping HLA-B*08:01 epitope EIYKR-
WII (Gag 260-267) [22] and thus is likely to have been 
originally selected in an HLA-B*08:01-positive subject 
prior to transmission to R096. 
Mechanism of distinct phylogenetic clustering of R097 
sequences following progression
Comparison of the viral sequences in R097 at ‘time 0’ 
and the cluster following progression 2.0–3.4 years later 
showed dramatic differences, prompting the hypoth-
esis that R097 might have progressed as a consequence 
of HIV superinfection. To determine whether the dra-
matic sequence changes observed were likely to be the 
result of superinfection, or of multiple escape mutations 
being selected over a short period of time to give the 
R097 >2 years:
includes 11 late
sampling mepints
1ca
R096 donor 0 years
R097 0 years11
0.02
nucleode
substuons/site
b
Fig. 1 Plasma HIV RNA viral load and CD4+ T cell counts for HLA-B*27:05/57:01+ subject R097 and his transmission partner R096 and phylogenetic 
analysis of HIV sequences showing epidemiological linkage and sequence diversity in transmission pair R096/R097. a Transmission pair donor, R096. 
b Transmission pair recipient, R097. ‘Early’ and ‘late’ time points of sampling for sequencing are shown (see c). ‘Time 0’ represents the time of diagno-
sis of recipient R097. The horizontal dotted line represents the limit of detection (LOD) of the viral load assay (40 HIV RNA copies/ml). Grey shading 
indicates the period during which the subject received antiretroviral (ART) therapy. c Maximum likelihood phylogenetic tree of 1091 bp alignment 
of RNA (ultra-deep consensus) sequences across the Gag p17 and p24 genes. The donor R096 sequence is shown in blue. Early and late sequenc-
ing time points are shown in a. The early R097 sequences are shown in red (n = 2). The late (post-2 year) sequences for R097 are shown in green 
(n = 11). The early and late sequences form two distinct clusters indicating considerable intra-host sequence diversification over time. 143 B clade 
reference sequences from the US and UK collected between 2003 and 2011 from the Los Alamos database (http://www.hiv.lanl.gov/) are shown in 
black. Bootstrap values for the R097 sequence clusters based on 1000 bootstrap replicates are shown in italics
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appearance of superinfection, we first sought evidence of 
escape within HLA-B*27:05 and HLA-B*57:01-restricted 
epitopes selected between ‘time 0’ and 2.0  years later 
(Table 2). In patient R097 between ‘time 0’ and 2.0 years 
later, we examined 17 HLA-B*27:05/57:01 epitopes previ-
ously shown to contain well-characterised footprints [22], 
and found escape mutants in 12 of these (one muta-
tion being contained in two overlapping HLA-B*27:05 
and HLA-B*57:01 epitopes in Vpr). Additional mutants 
were observed that were selected between ‘time 0’ and 
2.0 years later in HLA-B*27:05/57:01 restricted epitopes, 
but where HLA footprints have not been described (for 
example in the HLA-B*27:05 epitope GRRGWEALKY). 
Thus a proportion of the amino acid differences between 
the ‘time 0’ sequence and the viral sequences post pro-
gression can be explained by the selection of escape 
mutants in R097. However this did not distinguish rapid 
selection of escape mutants from the possibility of super-
infection with an HIV variant carrying multiple HLA-
B*27:05 and HLA-B*57:01-associated escape variants.
To examine this further, we analysed the timing of 
selection of escape mutants in R097 using ultra-deep 
sequencing (Table  3). At ‘time 0’ in R097, many of the 
escape variants that had reached fixation 2.0  years later 
were already present at low frequencies. For exam-
ple, Gag-A146P was present at 19%, Gag-T242N at 4%, 
Gag-R264K at 3%, and Pol-T839N at 50% in R097 at 
‘time 0’, and all were present at 99 or 100% 2.0 years later. 
Each of these variants were present in 0% of viruses in 
R096 at ‘time 0’. These data are consistent with the rapid 
increase in frequency of escape mutations in multiple 
epitopes restricted by HLA-B*27:05 and HLA-B*57:01 in 
the 2  years after ‘time 0’, but clearly selection of escape 
mutants had already been initiated by ‘time 0’.
However, two features of the sequence data argue 
strongly in favour of superinfection having occurred 
in R097. First, some of the escape mutants selected at 
‘time 0’ and not shared at the ‘time 2.0’ timepoint, and 
vice versa, are relatively rare. Examples here are A248E 
(87% at ‘time 0’ and 0% at ‘time 2.0’), which is a highly 
effective escape mutant [18], and S148T (0% at ‘time 0’ 
and 100% at ‘time 2.0’). Both of these mutants are within 
HLA-B*57:01-restricted CTL epitopes, but they are 
not selected sufficiently often to be included as HLA-
B*57:01-associated ‘footprints’ [22]. In contrast, many 
of the HLA-B*27:05/B*57:01-associated escape mutants 
present both at ‘time 0’ and 0% at ‘time 2.0’, such as 
T242N and R264K, are commonly observed footprints 
for these HLA alleles [22], and could easily have arisen 
independently in the two viruses in different subjects 
expressing HLA-B*27:05/57:01. Second, the number of 
amino acid differences between the viruses at ‘time 0’ and 
Table 1 HLA-B*51:01 and HLA-B*13:02 footprints in the recipient R097 sequence
For each epitope the B clade consensus sequence is represented as the top line. The R096 (donor) sequence is represented on the middle line, and the R097 (recipient) 
sequence at time 0 on the bottom line. Polymorphisms that represent previously described HLA-associated footprints [22] underlined. Sequences where an HLA-
associated footprint does not fall within a described epitope are shaded in grey
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at ‘time 2.0’ across the full-length proteomes numbered 
810. Less than 3% of these amino acid changes (19/810) 
can be ascribed to escape arising within epitopes that 
are restricted by the HLA alleles expressed by R097. 
Thus the dramatic sequence changes observed in R097 
between ‘time 0’ and 0% at ‘time 2.0’ cannot have been 
driven by CTL escape alone, but are consistent with HIV 
superinfection.
HCV co‑infection as an additional explanation for rapid 
immunological escape
Having established that HIV superinfection was likely 
to account for the rapid evolutionary changes in HIV 
sequences and disease progression in subject R097, we 
considered alternative explanations for the uncharac-
teristic speed of progression in an HLA B*27/B*57-pos-
itive individual. At the time of peak HIV viraemia (time 
2.0  years) the recipient was diagnosed with hepatitis 
C virus (HCV) genotype 1a co-infection by PCR (viral 
load 4.03 log copies/ml), although his HCV antibody 
test remained negative for a further 2.5  years before he 
finally seroconverted. An HCV RNA test 10 months ear-
lier (that is, 14 months after ‘time 0’) had been negative. 
He went on to receive treatment with IFNα/Ribavirin 
for 24  weeks, starting 5 months after the HCV diagno-
sis was made, although this did not result in clearance. 
Although HCV coinfection typically accelerates disease 
progression in HIV infection [23], in subject R097, as 
Table 2 Donor R096 and recipient R097 viral sequences encoding HLA-B*27:05/B*57:01-restricted epitopes
Epitopes showing evidence of CTL driven evolution in R097 are highlighted in grey
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described above, escape mutants in multiple HIV-spe-
cific HLA-B*27:05- and HLA-B*57:01-restricted epitopes 
had already been selected, and the viral load was on an 
upward trajectory, more than a year prior to the HCV 
infection. Nonetheless, it is evident that HIV superin-
fection occurred either simultaneous with, or weeks-to-
months before, HCV co-infection. In either case, HCV 
co-infected is likely to have accelerated the speed of pro-
gression to AIDS in this subject.
Lack of sequence diversification in an 
HLA‑B*27:05/57:01‑positive non‑progressor
To contrast the speed and extent of viral escape in the 
HLA-B*27:05/57:01-positive rapid progressor, R097, even 
before superinfection had occurred, with the sequence 
changes that might be expected in a non-progressor, we 
analysed gag viral sequences over a 10-year period in 
an ART-naive HLA-B*27:05/57:01-positive individual 
RI088, whose viral loads remained at  <  1000 copies/ml, 
and at  <  40 copies/ml for much of this period (Fig.  2). 
In this instance, viral sequence diversification was neg-
ligible with 1.1% difference in Gag at the amino acid 
level over 10 years. In contrast, we saw a 12% difference 
at the amino acid level in Gag over 2 years in the rapid 
progressor R097. Analysis of viral sequence at the clonal 
level in RI088 (Table 4, Additional file 2: Figure 1) shows 
that escape mutants were generated periodically but 
not always selected. For example, the most commonly 
selected variant, T242N, within the HLA-B*57:01 epitope 
TSTLQEQIGW (Gag 240–249), reached a frequency of 
55% 1.4 years after diagnosis, but subsequently declined 
to 0% (at 3.4  years) before being selected later. Variants 
within KF11 and KK10 were observed transiently and 
at low frequencies. The relative lack of sequence change 
in the virus in RI088 is also reflected in persistence of 
CTL responses, such as to the HLA-B*27:05-restricted 
Gag epitope KK10 and the HLA-B*57:01-restricted Nef 
epitope HW9 (Fig.  3). In contrast, although these same 
responses are present at ‘time 0’ in R097, they declined in 
association with the selection of escape (Fig. 3).  
Progression to AIDS in subject R097 associated 
with increasing viral replicative capacity
One of the mechanisms that has been proposed for HLA-
B*27:05 and HLA-B*57:01-mediated protection against 
progression to HIV disease is the observation that the 
Gag escape mutations associated with these HLA mol-
ecules significantly reduce viral replicative capacity [5, 
24–27]. Thus, even if the virus succeeds in evading the 
effective Gag-specific CTL responses restricted by HLA-
B*27:05/57:01, the cost of reduced VRC facilitates main-
tained control of HIV through other immune responses 
Table 3 Ultra-deep RNA sequencing of HLA-B*57:01 and HLA-B*27:05-restricted epitopes and associated compensatory 
positions from R097 and his transmission partner R096
Depth of coverage ranges from 46 to 85,000 reads. Epitopes at which predictable footprints [22] are selected in the donor are shown. The early selection of escape and 
compensatory mutations in the minor variant populations are shown in bold italics
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Fig. 2 Clinical course of infection and phylogenetic analysis of viral sequences from HLA-B*27:05/57:01-positive controller RI088. a Plasma HIV viral 
load and CD4+ T cell count for HLA-B*27:05/B*57:01-positive recipient RI088. ‘Time 0’ represents the time of diagnosis. The horizontal dotted line 
represents the limit of detection (LOD) of the viral load assay (40 copies/ml). b Maximum likelihood phylogenetic tree of a 1089 bp alignment of the 
Gag gene sequenced from proviral DNA (consensus of clonal sequences shown in Table 4). Subject RI088 (n = 6) sequences spanning 10 years are 
shown in red. 180 B clade reference sequences from the US and UK collected between 2003 and 2011 from the Los Alamos database (http://www.
hiv.lanl.gov/) are shown in black. Bootstrap values for the RI088 sequence cluster based on 1000 bootstrap replicates are shown in italics
Table 4 Clonal Sequencing of HIV proviral DNA at HLA‐B*57:01 and HLA-B*27:05-restricted Gag epitopes from controller RI088
The number of clones sequenced at each timepoint and number of independent PCR reactions from which PCR product was cloned are given. The percentage of 
clones with each sequence haplotype is shown. The most prevalent (consensus) epitope sequence is shown in black. Lower frequency variant sequences are shown in 
grey.
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from which the virus has not escaped. However, it is also 
well-described that reductions in viral replicative capac-
ity resulting from selection of certain escape mutants 
are typically mitigated, to a varying degree, by selection 
of alternative escape mutants [28] and the co-selection 
of compensatory mutants [27, 29–31]. To investigate 
whether VRC was substantially reduced in the face of the 
selection of, or superinfection by a virus carrying, multi-
ple Gag escape mutants in R097, we generated chimeric 
viruses comprising NL4-3 and the autologous gag-pro 
sequence from R097 (Fig. 4a). At ‘time 0’, when the viral 
load was low and the CD4+ T cell count was high, the 
VRC in R097 was substantially lower than  both NL4-3 
wildtype and ‘time 0’ R096 virus. However, during the 
course of progression, the VRC ultimately had increased 
to an intermediate level (at 3.4 years after ‘time 0’), 
reflecting some successful correction of fitness costs of 
escape variants by compensatory mutants or by the selec-
tion of alternative, higher fitness escape mutants. In con-
trast, although in the case of RI088 the transmitted virus 
was not known, the lack of multiple Gag escape mutants 
in RI088 appeared to have little impact on VRC com-
pared to wildtype NL4-3 (Fig.  4b). These data are con-
sistent with previous findings that the HLA-B*27:05- and 
HLA-B*57:01-associated escape mutants in Gag reduce 
viral replicative capacity, but even a relatively disabled 
virus can drive rapid progression to AIDS in the absence 
of effective HIV-specific CD8+ T cell activity.
Discussion
We here describe two HIV-infected adults who express 
both HLA-B*27:05 and HLA-B*57:01, the most protec-
tive HLA class molecules against HIV disease progres-
sion, one of whom is a typical long-term non-progressor, 
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Fig. 3 HIV-specific CTL responses in progressor R097 and in non-progressor RI088. EliSpot assays tested recognition of overlapping 18mer peptides, 
which together spanned the B clade proteome. The figure includes the full sequence of each 18mer peptide recognised and the HLA restriction 
where known, with known optimal epitopes shown in bold. a EliSpot responses detected in progressor R097 at time 0 (diagnosis) and 2.0 years 
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18mer peptides containing the epitopes ISPRTLNAW or STTVKAACWW at either timepoint. b Responses detected in non-progressor RI088 at the 
times shown post diagnosis. Selected peptides that were strongly recognized in R097 but not in RI088 are included in panel B
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maintaining low-to-undetectable viral loads over more 
than a decade of follow up, whilst the other is a rapid pro-
gressor, whose CD4+ T cell decline from immune control 
of HIV to AIDS occurs within a period of 3 years. In the 
rapid progressor studied here, we have shown using ultra-
deep sequencing that escape mutations were selected in 
early infection across several of the known HLA-B*27:05 
and HLA-B*57:01 epitopes, from the earliest timepoint 
when the CD4+ T cell count was 950 cells/mm3 and viral 
load was 65 copies/ml, preceding loss of immune con-
trol. However, the most dramatic viral sequence changes 
observed in this subject, coincident with rapid progres-
sion to AIDS, were associated with superinfection with 
a virus whose ancestry is substantially different from the 
original transmitted strain of HIV. Although many of the 
classical HLA-B*27:05 and HLA-B*57:01 ‘footprints’ [22] 
were present both pre- and post-superinfection, these 
commonly arise predictably and independently in individ-
uals expressing these HLA molecules, and > 96% of amino 
acid changes were unrelated to CTL-driven escape.
In contrast, very little viral sequence change 
occurred over more than a decade in the non-progres-
sor. Clonal sequencing reveals that escape mutants 
were generated all of this time, but in the majority of 
instances these were not selected. Finally, analysis 
of the viral replicative capacity (VRC) of the viruses 
in the two subjects revealed that differential rates of 
progression were not explained by lower VRC in the 
non-progressor. On the contrary, rapid progression 
occurred despite reductions in VRC in the subject with 
progressive disease.
Approximately 16% of Caucasians express HLA-
B*27:05 and/or HLA-B*57:01 and  ~  60% of Caucasian 
elite controllers—approximately 0.3% of infected individ-
uals overall [18]—express one or the other of these alleles 
[18]. Therefore, only a minority of individuals express-
ing HLA-B*27:05 and/or HLA-B*57:01—approximately 
2%—become elite controllers, for reasons which remain 
unclear. Factors proposed to explain differential outcome 
in subjects with matched HLA-B allele expression may 
be categorised as immunological, genetic and virological. 
Immunological factors include breadth of the Gag-spe-
cific CTL response [3], avidity of the T cell receptor for 
the peptide-MHC complex [32], and ability of the TCR 
repertoire to recognise potential escape variants [33]. 
Genetic factors include the HLA-A and HLA-C [34, 35] 
and KIR alleles expressed [36], and the presence of CCR5 
variants such as the delta-32 mutant [37]. Virological fac-
tors include replicative capacity of the transmitted virus 
and pre-adaptation of the transmitted virus to the HLA 
class I molecules expressed in the transmission recipient 
[38–41].
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A further influence on HIV disease outcome is the 
introduction of co-infection with another blood-borne 
virus. HCV may skew the immunological response to 
HIV, for example by increasing immune activation [42]. 
The immunological influence of HCV therapy on HIV 
is complex, as exemplified by the APRICOT study in 
which HCV/HIV co-infected patients receiving IFNα had 
a 1.0 log reduction in HIV viral load, but also a reduc-
tion in absolute CD4+ T cell counts [43]. In the patient 
we describe here, it is likely that intercurrent acute HCV 
infection (and/or IFN-based therapy) may have contrib-
uted to HIV progression. However, this co-infection can-
not explain the whole picture as changes in CD4+ T cell 
count and HIV viral load that herald progression to AIDS 
were already evident before the HCV infection occurred, 
and also the extent of the sequence changes observed can 
only be explained by HIV superinfection.
 In the case of the rapid progressor, the observation 
that several escape mutations were selected very early in 
the course of infection (prior to ‘time 0’) illustrates that 
the presence of a broad HIV-specific immune response 
does not provide complete protection against escape. 
Indeed, at the initial timepoint, when the CD4+ T cell 
count was 950 cells/mm3 and the HIV viral load was 65 
copies/ml, five CTL responses were detectable (Fig.  3). 
Perhaps more significant is the observation of variants 
being generated in viral sequences derived from the 
non-progressor RI088 that did not get selected. Taken 
together with the data showing the relatively high viral 
replicative capacity of virus derived from RI088 com-
pared to the R097 viruses, these findings are consistent 
with the quality of individual key HIV-specific responses 
being critical to outcome. These two case reports cannot 
provide definitive information on which specificities are 
most important to immune control, but are consistent 
with numerous previous studies indicating that the HLA-
B*27:05-KK10 response plays a vital role in immune con-
trol of HIV in subjects expressing HLA-B*27:05.
The influence of genetic factors other than the HLA-B 
type has not been evaluated in these two study sub-
jects. Although HLA-A and HLA-C alleles can influence 
immune control of HIV, HLA-B alleles have a greater 
impact than HLA-A or HLA-C [1, 35, 44]. The HLA-A 
alleles expressed by the progressor (A*11:01/24:02) and 
non-progressor (A*01:01/03:01) have not been associ-
ated with differential disease outcome and the HLA-C 
alleles expressed (C*02:02/06:02) were the same in both 
subjects.
 The changes in viral replicative capacity over time in 
R097 are of interest, showing an initial significant decrease 
in VRC as the B27/57 escape mutants are selected, and 
then a partial recovery towards the VRC of the original 
infecting strain from R096. These findings are consistent 
with many studies that have shown the ability of the virus 
to limit the cost of escape mutants either via the selection 
of alternative escape mutants [28] and/or the co-selection 
of compensatory mutants [27, 30, 31, 45–50]. However, 
although the VRC returns towards normal, it remains well 
below that of the original transmitted virus. In contrast, 
the VRC of the virus in the elite controller remains very 
close to the reference NL4-3 despite more than a decade of 
strong selection pressure on the virus.
Conclusions
The description here of two HIV-infected subjects 
expressing both HLA-B*27:05 and HLA-B*57:01 with 
differential disease outcomes demonstrates the rapidity 
with which progression can occur, even when HIV-spe-
cific CTL responses restricted by these protective alleles 
are present. In this report rapid progression occurred fol-
lowing HIV superinfection. However, only a small minor-
ity of subjects expressing protective HLA alleles remain 
non-progressors. Consistent with previous studies, quali-
tative aspects of the HIV-specific CTL response are likely 
to play a critical part in maintaining long-term immune 
control of HIV infection.
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